



Rajasthan Medical Services Corporation Limited

Gandhi Block, SwasthyaBhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 ,2228064 Fax No. 0141-2228065 Website: <http://rmsc.health.rajasthan.gov.in>

CIN:U24232RJ2011SGC035067

E_mail :edprmsc@nic.in

Ref. No.:- F.02(336)/RMSCL/PROCUREMENT/DRUG/NIB-26/2021/1775

Dated:- 1.10.21

Corrigendum – II

Subject:- Amendments in BOQ/ technical specification/Eligibility Criteria.

Ref.:- NIB No. F.02(336)/RMSCL/PROCUREMENT/DRUG/NIB-26/2021 Dated:- 08.10.2.2021


(Technical bid opening due on dated -12.11.2021)

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).																																																
1.	<p>Annexure-VIII and BOQ:-</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> <th>Packing Unit</th> </tr> </thead> <tbody> <tr> <td>166</td> <td>Deferasirox Tablets 500 mg</td> <td>30 Tab</td> </tr> <tr> <td>185</td> <td>Amlodipine Tablets IP 5 mg</td> <td>10x10 Tab Blister</td> </tr> <tr> <td>340</td> <td>Alprazolam Tab IP 0.5mg [340]</td> <td>10x10 Tab Blister</td> </tr> <tr> <td>714</td> <td>Inj Clindamycin phosphate IP 300 mg</td> <td>Vial</td> </tr> <tr> <td>721</td> <td>Tab. Terbinafine Hydrochloride 250 mg</td> <td>10X10</td> </tr> <tr> <td>797</td> <td>Tab Dasatinib 100mg</td> <td>60 Tab</td> </tr> <tr> <td>114A</td> <td>Fluconazole Tab, IP 150mg</td> <td>10x10x1 Tab Strip</td> </tr> </tbody> </table>	Code No.	Name of item with specification	Packing Unit	166	Deferasirox Tablets 500 mg	30 Tab	185	Amlodipine Tablets IP 5 mg	10x10 Tab Blister	340	Alprazolam Tab IP 0.5mg [340]	10x10 Tab Blister	714	Inj Clindamycin phosphate IP 300 mg	Vial	721	Tab. Terbinafine Hydrochloride 250 mg	10X10	797	Tab Dasatinib 100mg	60 Tab	114A	Fluconazole Tab, IP 150mg	10x10x1 Tab Strip	<p>Annexure-VIII and BOQ:-</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> <th>Amended Packing Unit</th> </tr> </thead> <tbody> <tr> <td>166</td> <td>Deferasirox Tablets 500 mg</td> <td>30 Tab OR 10 Tab (Rate should be quoted for 30 tablets)</td> </tr> <tr> <td>185</td> <td>Amlodipine Tablets IP 5 mg</td> <td>10x10 Tab Blister Or 1x30 Tab Blister (Rate should be quoted for 10X10 tablets)</td> </tr> <tr> <td>340</td> <td>Alprazolam Tab IP 0.5mg [340]</td> <td>10x10 Tab Blister/Strip OR 10x15 Tab Blister/ Strip (Rate should be quoted for 10X10 tablets)</td> </tr> <tr> <td>714</td> <td>Inj Clindamycin phosphate IP 300 mg</td> <td>Vial/Amp</td> </tr> <tr> <td>721</td> <td>Tab. Terbinafine Hydrochloride 250 mg</td> <td>10X10 Or 10x15/1x7 Tablet (Rate should be quoted for 10X10 tablets)</td> </tr> <tr> <td>797</td> <td>Tab Dasatinib 100mg</td> <td>60 Tab Or 10 Tab (Rate should be quoted for 60 tablets)</td> </tr> <tr> <td>114A</td> <td>Fluconazole Tab. IP 150mg</td> <td>10x10x1 Tab Strip (Perforated)</td> </tr> </tbody> </table>	Code No.	Name of item with specification	Amended Packing Unit	166	Deferasirox Tablets 500 mg	30 Tab OR 10 Tab (Rate should be quoted for 30 tablets)	185	Amlodipine Tablets IP 5 mg	10x10 Tab Blister Or 1x30 Tab Blister (Rate should be quoted for 10X10 tablets)	340	Alprazolam Tab IP 0.5mg [340]	10x10 Tab Blister/Strip OR 10x15 Tab Blister/ Strip (Rate should be quoted for 10X10 tablets)	714	Inj Clindamycin phosphate IP 300 mg	Vial/Amp	721	Tab. Terbinafine Hydrochloride 250 mg	10X10 Or 10x15/1x7 Tablet (Rate should be quoted for 10X10 tablets)	797	Tab Dasatinib 100mg	60 Tab Or 10 Tab (Rate should be quoted for 60 tablets)	114A	Fluconazole Tab. IP 150mg	10x10x1 Tab Strip (Perforated)
Code No.	Name of item with specification	Packing Unit																																																
166	Deferasirox Tablets 500 mg	30 Tab																																																
185	Amlodipine Tablets IP 5 mg	10x10 Tab Blister																																																
340	Alprazolam Tab IP 0.5mg [340]	10x10 Tab Blister																																																
714	Inj Clindamycin phosphate IP 300 mg	Vial																																																
721	Tab. Terbinafine Hydrochloride 250 mg	10X10																																																
797	Tab Dasatinib 100mg	60 Tab																																																
114A	Fluconazole Tab, IP 150mg	10x10x1 Tab Strip																																																
Code No.	Name of item with specification	Amended Packing Unit																																																
166	Deferasirox Tablets 500 mg	30 Tab OR 10 Tab (Rate should be quoted for 30 tablets)																																																
185	Amlodipine Tablets IP 5 mg	10x10 Tab Blister Or 1x30 Tab Blister (Rate should be quoted for 10X10 tablets)																																																
340	Alprazolam Tab IP 0.5mg [340]	10x10 Tab Blister/Strip OR 10x15 Tab Blister/ Strip (Rate should be quoted for 10X10 tablets)																																																
714	Inj Clindamycin phosphate IP 300 mg	Vial/Amp																																																
721	Tab. Terbinafine Hydrochloride 250 mg	10X10 Or 10x15/1x7 Tablet (Rate should be quoted for 10X10 tablets)																																																
797	Tab Dasatinib 100mg	60 Tab Or 10 Tab (Rate should be quoted for 60 tablets)																																																
114A	Fluconazole Tab. IP 150mg	10x10x1 Tab Strip (Perforated)																																																
2	<p>Clause 2(b) ELIGIBILITY CRITERIA (b)Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years 2016-17, 2017-18 & 2018-19 or 2017-18, 2018-19 & 2019-20 should not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years 2016-17, 2017-18 & 2018-19 or 2017-18, 2018-19 & 2019-20 should not be less than Rs. 2 Crore. For drug items falling in the category of Disinfectants</p>	<p>Clause 2(b) ELIGIBILITY CRITERIA (b)Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years 2016-17, 2017-18 & 2018-19 or 2017-18, 2018-19 & 2019-20 or 2020-2021 should not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years 2016-17, 2017-18 & 2018-19 or 2017-18, 2018-19 & 2019-20 or 2020-2021 should not be less than Rs. 2 Crore.</p>																																																

S. No	Existing condition / technical specification/Packing Unit/Quantity (clause no.)	Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).												
	& Antiseptics, Eye preparations and Ear drops etc (Item code 588, 614) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore.	For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc (Item code 588, 614) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore.												
3	Annexure-VIII and BOQ:- <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>344</td> <td>Chlorpromazine Tablets IP 25 mg (Sugar- Coated)</td> </tr> <tr> <td>728</td> <td>Tab Letrozole USP 2.5 mg (Each Film Coated Tablet contains Letrozole USP 2.5 mg)</td> </tr> </tbody> </table>	Code No.	Name of item with specification	344	Chlorpromazine Tablets IP 25 mg (Sugar- Coated)	728	Tab Letrozole USP 2.5 mg (Each Film Coated Tablet contains Letrozole USP 2.5 mg)	Annexure-VIII and BOQ:- <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>344</td> <td>Chlorpromazine Tablets IP 25 mg</td> </tr> <tr> <td>728</td> <td>Tab Letrozole IP 2.5 mg (Each Film Coated Tablet contains Letrozole IP 2.5 mg)</td> </tr> </tbody> </table>	Code No.	Name of item with specification	344	Chlorpromazine Tablets IP 25 mg	728	Tab Letrozole IP 2.5 mg (Each Film Coated Tablet contains Letrozole IP 2.5 mg)
Code No.	Name of item with specification													
344	Chlorpromazine Tablets IP 25 mg (Sugar- Coated)													
728	Tab Letrozole USP 2.5 mg (Each Film Coated Tablet contains Letrozole USP 2.5 mg)													
Code No.	Name of item with specification													
344	Chlorpromazine Tablets IP 25 mg													
728	Tab Letrozole IP 2.5 mg (Each Film Coated Tablet contains Letrozole IP 2.5 mg)													
4	Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID (c)Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 year standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also. <u>The period of Market Standing will be reckoned from the date of issue of Product Permission.</u>	Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID (c)Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The importer should have at least 3 year standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also. <u>The period of Market Standing will be reckoned from the date of issue of Product Permission.</u> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Relaxation in Condition of Market Standing Certificate</th> </tr> </thead> <tbody> <tr> <td>797</td> <td>Market Standing Certificate of one year accepted.</td> </tr> </tbody> </table>	Code No.	Relaxation in Condition of Market Standing Certificate	797	Market Standing Certificate of one year accepted.								
Code No.	Relaxation in Condition of Market Standing Certificate													
797	Market Standing Certificate of one year accepted.													
5	Technical Bid opening date of NIB No. F.02(336)/RMSCL/PROCUREMENT/DRUG/NIB-26/2021 Dated:- 08.10.2021 is 11.00 AM of 12.11.2021. <table border="1"> <tbody> <tr> <td>Last date and time of submission of online bids</td> <td>09.11.2021 at 6.00 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan and Physically</td> <td>09.11.2021 at 6.00 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>10.11.2021 at 11.00 AM</td> </tr> </tbody> </table>	Last date and time of submission of online bids	09.11.2021 at 6.00 PM	EMD, Tender fees, RISL fees through challan and Physically	09.11.2021 at 6.00 PM	Date and time of opening of Online technical bids	10.11.2021 at 11.00 AM	Technical Bid opening date of F.02(336)/RMSCL/PROCUREMENT/DRUG/NIB-26/2021 Dated:- 08.10.2021 is 11.00 AM of 23.11.2021. <table border="1"> <tbody> <tr> <td>Last date and time of submission of online bids</td> <td>22.11.2021 at 6.00 PM</td> </tr> <tr> <td>EMD, Tender fees, RISL fees through challan and Physically</td> <td>22.11.2021 at 6.00 PM</td> </tr> <tr> <td>Date and time of opening of Online technical bids</td> <td>23.11.2021 at 11.00 AM</td> </tr> </tbody> </table>	Last date and time of submission of online bids	22.11.2021 at 6.00 PM	EMD, Tender fees, RISL fees through challan and Physically	22.11.2021 at 6.00 PM	Date and time of opening of Online technical bids	23.11.2021 at 11.00 AM
Last date and time of submission of online bids	09.11.2021 at 6.00 PM													
EMD, Tender fees, RISL fees through challan and Physically	09.11.2021 at 6.00 PM													
Date and time of opening of Online technical bids	10.11.2021 at 11.00 AM													
Last date and time of submission of online bids	22.11.2021 at 6.00 PM													
EMD, Tender fees, RISL fees through challan and Physically	22.11.2021 at 6.00 PM													
Date and time of opening of Online technical bids	23.11.2021 at 11.00 AM													

Note:-

- It may be noted that if any further amendments are issued then a corrigendum will be published and informed.
- Rest of the terms and conditions will remain the same.


Executive Director (Proc.)
RMSCL